Inventiva to Present at the J.P. Morgan Healthcare Conference in January
The biopharmaceutical company Inventiva announced that its CEO, Andrew Obenshain, will speak at the 44th annual J.P. Morgan Healthcare Conference, which will be held in San Francisco in mid-January.
According to the company's press release, Andrew Obenshain will provide an overview of the company on Thursday, January 15, 2026, from 9:00 AM to 9:40 AM Pacific Time. The presentation will take place at the Westin St. Francis Hotel in San Francisco, California. The session will be broadcast live and available for replay on the company's website at https://inventivapharma.com/fr/investisseurs/presentations/. The J.P. Morgan Healthcare Conference, running from January 12 to January 15, 2026, is a major event in the biopharmaceutical sector.
Additional Meetings
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
In addition to the official presentation, Inventiva's management team will participate in bilateral meetings with investors, the company states. These individual meetings are scheduled for Wednesday, January 14, 2026, the day before the public presentation. These meetings typically allow executives to discuss in detail the company's strategy and development programs with institutional investors.
Research Focus
According to the company, Inventiva focuses on the development of orally administered small molecules for the treatment of steatohepatitis associated with metabolic dysfunction, also known as MASH. The company is currently evaluating Lanifibranor in a pivotal Phase 3 clinical study for the treatment of adult patients with this chronic liver disease. Inventiva is listed on compartment B of the regulated market of Euronext Paris and on the Nasdaq Global Market in the United States under the symbol IVA.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
